EUCTR2016-002467-34-DE进行中（未招募）1 期
al-IRI with 5-fluorouracil (5-FU) and leucovorin or gemcitabine plus cisplatin in advanced biliary-tract cancer - An open label, non-comparative, randomized, multicenter phase II trial - NIFE
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 92
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Written informed consent including participation in translational research and any locally-required authorization (EU Data Privacy Directive in the EU) obtained from the subject prior to performing any protocol-related procedures, including screening evaluations
- •2.Age = 18 years at time of study entry
- •3.Histologically confirmed, non-resectable, locally advanced or metastatic adenocarcinoma of the intrahepatic or extrahepatic biliary tract
- •4.Non-resectability has to be stated by local interdisciplinary tumor board
- •5.Measurable or assessable disease according to RECIST 1.1
- •6.ECOG performance status 0-1
- •7.Life expectancy of more than 3 months
- •8.If applicable, adequately treated biliary tract obstruction before study entry with total bilirubin concentration = 2 x ULN
- •9.Adequate blood count, liver-enzymes, and renal function:
- •White blood cell count = 3.5 x 106/mL
- •Platelet count = 100 x 109/L (>100,000 per mm3)
- •AST (SGOT)/ALT (SGPT) = 5 x institutional upper limit of normal
- •Serum Creatinine = 1.5 x institutional ULN and a calculated glomerular filtration rate = 30 mL per minute
- •10.Patients not receiving therapeutic anticoagulation must have an INR < 1.5 ULN and PTT < 1.5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is allowed as long as the INR or PTT is within therapeutic limits (according to the medical standard in the institution) and the patient has been on a stable dose for anticoagulants for at least three weeks at the time of randomization
- •11.No prior palliative chemotherapy for biliary tract cancer
- •12.No adjuvant treatment within 6 months prior to study entry
- •13.Subject is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 46
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 46
排除标准
- •1.Active uncontrolled infection, chronic infectious diseases, immune deficiency syndromes
- •2.Premalignant hematologic disorders, e.g. myelodysplastic syndrome
- •3.Clinically significant cardiovascular disease (incl. myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before enrollment
- •4.Prior (<3 years) or concurrent malignancy (other than biliary-tract cancer) which either progresses or requires active treatment. Exceptions are: basal cell cancer of the skin, pre-invasive cancer of the cervix, T1a or T1b prostate carcinoma, or superficial urinary bladder tumor [Ta, Tis and T1].
- •5.Pre-existing lung disease
- •6.History or clinical evidence of CNS metastases
- •Exceptions are: Subjects who have completed local therapy and who meet both of the following criteria:
- •a)are asymptomatic and
- •b)have no requirement for steroids 6 weeks prior to start of study treament. Screening with CNS imaging (CT or MRI) is required only if clinically indicated or if the subject has a history of CNS metastases
- •7.History of hypersensitivity to any of the study drugs or any of the constituents of the products
- •8.Known dihydropyrimidine dehydrogenase (DPD) deficiency
- •9.Allogeneic transplantation requiring immunosuppressive therapy or other major immunosuppressive therapy
- •10.Severe non-healing wounds, ulcers or bone fractions
- •11.Evidence of bleeding diathesis or coagulopathy
- •12.Major surgical procedures, except open biopsy, nor significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgical procedure during the course of the study except for surgery of central intravenous line placement for chemotherapy administration.
- •13.Medication that is known to interfere with any of the agents applied in the trial.
- •14.Female subjects who are pregnant, breast-feeding or male or female patients of reproductive potential who are not employing an effective method of birth control (failure rate of less than 1% per year). [Acceptable methods of contraception are: implants, injectable contraceptives, combined oral contraceptives, intrauterine pessars (only hormonal devices), sexual abstinence or vasectomy of the partner]. Women of childbearing potential must have a negative pregnancy test (serum ß-HCG) at Screening.
- •15.Any condition or comorbidity that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results
- •16.Known Gilbert-Meulengracht syndrome
- •17.Known chronic hypoacusis, tinnitus or vertigo
- •18.Participation in another clinical study with an investigational product during the last 30 days before inclusion or 7 half-lifes of previously used trial medication, whichever is of longer duration.
- •19.Previous enrollment or randomization in the present study (does not include screening failure).
- •20.Any other chemotherapy at study start
- •21.Involvement in the planning and/or conduct of the study (applies to both Servier staff and/or staff of sponsor and study site)
- •22.Patient who might be dependent on the sponsor, site or the investigator
- •23.Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities § 40 Abs. 1 S. 3 Nr. 4 AMG.
- •24.Patients who are unable to consent because they do not understand the nature, significance and implications of the clinical trial and therefore cannot form a rational intention in
研究者
相似试验
进行中（未招募）
1 期
5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 studybiliary tract cancer not amedable for curative resection with progressive disease after first-line chematherapy with gemcitabine and cisplatinEUCTR2015-004028-69-DEGoethe-Universität Frankfurt, PD Fabian Finkelmeier56
招募中
2 期
5-Fluorouracil (5-FU), folinic acid and irinotecan (FOLFIRI) versus 5-FU and folinic acid as second-line chemotherapy in patients with biliary tract cancer (IRIBIL): a randomized open-label phase 2 studyC22C23Malignant neoplasm of liver and intrahepatic bile ductsMalignant neoplasm of gallbladderDRKS00012595Dekanat des Fachbereichs MedizinUniversitätsklinikum der Goethe-Universität Frankfurt27
进行中（未招募）
1 期
Phase 1b trial of 5-fluorouracil, leucovorin, irinotecan in combination with temozolomide (FLIRT) and bevacizumab for the first-line treatment of patients with MGMT silenced, microsatellite stable metastatic colorectal cancer.metastatic colorectal cancerMedDRA version: 27.0Level: LLTClassification code: 10052362Term: Metastatic colorectal cancer Class: 10029104MedDRA version: 20.0Level: SOCClassification code: 10029104Term: Neoplasms benign malignant and unspecified (incl cysts and polyps) Class: 2CTIS2024-515580-64-00Fondazione IRCCS Istituto Nazionale Dei Tumori18
已完成
不适用
Feasibility study of 5-fluorouracil, leucovorin and paclitaxel (FLTAX) in peritoneal disseminated gastric cancer with massive ascites or inadequate oral intakeGastric cancerJPRN-UMIN000002093ational Cancer Center Hospital20
进行中（未招募）
1 期
A phase I study of FLOT in metastatic gastric cancerGastric cancerJPRN-jRCTs041200044Masuishi Toshiki36